Trocef-TZ Injection

Introduction

Trocef-TZ is a prescription medication that contains two active ingredients: Cefoperazone and Tazobactam. It is commonly used to treat various bacterial infections. It is available under the brand name Trocef-TZ.

Uses

Trocef-TZ is indicated for the treatment of a wide range of infections caused by susceptible bacteria. It is commonly prescribed for conditions such as respiratory tract infections, urinary tract infections, skin and soft tissue infections, intra-abdominal infections, and septicemia. Your healthcare provider will determine whether Trocef-TZ is the appropriate treatment for your specific infection.

Dosage and Administration

Trocef-TZ should be administered under the supervision of a healthcare professional. The dosage and duration of treatment will depend on the severity of the infection, the patient’s age, and other individual factors. It is typically given as an intravenous infusion over a specified period of time. Follow your healthcare provider’s instructions regarding the correct dosage and administration schedule.

Mechanism of Action

Trocef-TZ combines two active ingredients: Cefoperazone and Tazobactam. Cefoperazone is a broad-spectrum antibiotic that works by inhibiting the growth of bacteria. Tazobactam is a beta-lactamase inhibitor that helps to enhance the activity of Cefoperazone by preventing the breakdown of the antibiotic by certain bacteria. Together, these ingredients help to effectively combat bacterial infections.

Side Effects

Common side effects may include nausea, vomiting, diarrhea, headache, and local reactions at the injection site. These side effects are usually mild and transient. However, if you experience any severe or persistent side effects, seek medical attention immediately.

Drug Interactions

Trocef-TZ may interact with certain medications, including other antibiotics, anticoagulants, and certain medications used to treat gout. Inform your healthcare provider about all the medications you are currently taking, including prescription, over-the-counter, and herbal products, to avoid potential drug interactions.

Precautions

Before using Trocef-TZ, inform your healthcare provider about any known allergies or sensitivities to Cefoperazone, Tazobactam, or any other medications. Disclose your medical history, especially if you have a history of kidney disease or any other significant medical condition. Trocef-TZ should be used with caution in patients with certain conditions, and your healthcare provider will assess the potential risks and benefits before prescribing it.

Storage

Patient Tips

• Follow the dosage and administration instructions provided by your healthcare provider.
• If you miss a dose, contact your healthcare provider for guidance on how to proceed.
• Report any unusual side effects or symptoms to your healthcare provider.
• Take the full course of treatment prescribed by your healthcare provider, even if you start to feel better before completing the treatment.
• Do not share your medication with others, as it is prescribed specifically for your condition.
• If you have any questions or concerns about your treatment, consult your healthcare provider for clarification and guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Cefoperazone (Drugs.com) [Accessed 18 Jun. 2024] (online) Available at:
• LactMed: Drugs and Lactation Database (National Library of Medicine) [Accessed 17 Jun. 2024] (online) Available at:
• Wang Z, Li Z, Luo S, Yang Z, Xing Y, Pu C, Dong J. Cefoperazone and sulbactam-related eosinophilic peritonitis: a case report and literature review. J Int Med Res. 2021 Jun;49(6):3000605211025367. doi: 10.1177/03000605211025367. [Accessed 3 Jun. 2024] Available at:
• Parker SW, Baxter J, Beam TR Jr. Cefoperazone-induced coagulopathy. Lancet. 1984 May 5;1(8384):1016. doi: 10.1016/s0140-6736(84)92351-1. [Accessed 25 Jun. 2024] Available at: